The Maryland Cannabis Administration (MCA), formerly the Maryland Medical Cannabis Commission (MMCC), sponsored this “post-legalization” survey and report from Cannabis Public Policy Consulting (CPPC) to examine similarities and differences in patient perceptions and behavior prior to and following legalization of cannabis in Maryland for adults 21+. The MMCPS-23 follows the first wave MMCPS-22, a “pre-legalization” survey that was conducted in September 2022, prior to the ballot referendum in which voters approved legalization of the sale of cannabis to adults 21 and over beginning July 1, 2023. As with the MMCPS-22, more than 15,000 patients took part in the MMCPS- 23 survey, conducted in September 2023, approximately three months after the start of adult-use sales in the State. This report details the extent to which key measures of
interest changed with expanded legalization, including patterns of use, perceptions of risk and benefit, and the occurrence of high-risk behaviors related to cannabis use.
Cannabis Application Scoring Challenges Observed Across the Country
License Caps for State Cannabis Programs
An Examination of The Virginia Medical Cannabis Market
2024 RDCOS Outcomes
April2024_RDCOS Data Catalog 1
CPPC’s Response to Congress Regarding Approaches to Regulating CBD
In January 2023, FDA announced that it would like to work with Congress to craft a legislative approach to the regulation of CBD products.
STAY INFORMED ON CPPC'S RESEARCH AND PROJECTS

